DMD Warrior

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Powered by Hostinger

Latest Articles

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

Research July 24, 2026 0

For families affected by Duchenne muscular dystrophy (DMD), every...

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Editorials July 22, 2026 6

The landscape of Duchenne muscular dystrophy (DMD) research is...

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen, an Exon 51 Skipping Therapy for Duchenne Muscular Dystrophy (DMD)

Press Releases July 20, 2026 0

Families affected by Duchenne muscular dystrophy (DMD) received encouraging...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Therapies December 26, 2024 4

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Editorials April 10, 2026 9

The landscape of potential new gene therapies for Duchenne...

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control

Editorials April 6, 2026 2

The duchenne muscular dystrophy treatment cost has become one...

Duchenne MD

Genetic

Care Guidelines

Health Guidelines

Latest Posts

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen, an Exon 51 Skipping Therapy for Duchenne Muscular Dystrophy (DMD)

Latest Posts

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen, an Exon 51 Skipping Therapy for Duchenne Muscular Dystrophy (DMD)

Santhera Expands Biomedica Agreement to Extend AGAMREE (Vamorolone) Distribution Across Central Asia and the Caucasus

Don't Miss

Constipation in Duchenne Muscular Dystrophy: Causes, Symptoms & Treatment

Calcium in Duchenne Muscular Dystrophy: Mechanisms, Risks, and Treatment Insights

Why CK, AST, and ALT Data Matter More Than Videos in Duchenne Gene Therapy

Does My Child Have Duchenne Muscular Dystrophy (DMD)?

ELEVIDYS ENHANCE Study: A Phase 4 Trial Begins to Evaluate Safety and Effectiveness in Duchenne Muscular Dystrophy

About us

Latest Articles

Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027

7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen, an Exon 51 Skipping Therapy for Duchenne Muscular Dystrophy (DMD)

Most Popular

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control